dexamethasone
dexamethasone: developed by 2 companies · 205 clinical trials tracked · 2 FDA decisions.
dexamethasone evidence translation
What we can confirm
2 FDA records · 205 tracked trials
What it means
What to watch
Prepared research question
What is verified about dexamethasone, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 33 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| AbbVie Inc. (ABBV) | Approved |
| OCULAR THERAPEUTIX, INC (OCUL) | Approved |
Clinical Trials (205)showing 10 most recent
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Primary endpoint: RAGE Antagonist FPS-ZM1 (FPS-ZM1) related adverse events
An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor
Primary endpoint: Superiority of progression free survival (PFS)
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)
Primary endpoint: Safety Run-In: Number of Participants With Adverse Events (AE)s
A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Primary endpoint: Number of Participants With Adverse Events
A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)
Primary endpoint: Dose limiting toxicities (Safety run-in: Cohort A)
A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)
Primary endpoint: Progression to severe dengue/critical dengue
A Phase 1/2a, Open-Label, Dose Finding and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sonrotoclax (BGB-11417) in Combination With Other Agents in Pediatric Patients Aged 6 Months to 17 Years, With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Phase I Pilot Trial of Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
Primary endpoint: Safety of Golcadomide + Pemetrexed, Rituximab and Dexamethasone
A Phase 2 Trial of Early Enhanced Interventions to Prevent ICANS After CD19 CAR T Therapy in Patients With Non-Hodgkin Lymphoma: Lazarus Trial
Primary endpoint: Efficacy of IT therapy to reduce high-grade ICANS in participants who receive axi-cel in NHL compared to historical experience
Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of MK-2010 in Combination With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants Who Experience an Adverse Event (AE)
FDA Decisions2 records
Frequently asked questions
Who is developing dexamethasone?
dexamethasone is being developed by AbbVie Inc., OCULAR THERAPEUTIX, INC.
How many clinical trials involve dexamethasone?
BioSniper tracks 205 clinical trials involving dexamethasone.
What is dexamethasone's latest FDA decision?
The most recent tracked FDA decision for dexamethasone is Approval for 1 INDICATIONS AND USAGE DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. ( 1.1 ). The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedu, dated November 30, 2018.